Research Summaries

New Targeted Therapy for Chronic Lymphocytic Leukemia Shows Promise

ASCO Annual Meeting
May 15, 2013

In early, ongoing research, the drug, idelalisib helped to shrink tumors for patients with recurrent or treatment-resistant chronic lymphocytic leukemia (CLL). CLL is a slow-growing cancer and many patients do not need treatment until they start having symptoms. However, after treatment, most patients will have the disease come back, called recurrent or relapsed CLL. About 20% of patients will develop treatment-resistant or refractory CLL, meaning the disease comes back quickly or the original treatment did not work.

Patients with Lung Cancer Harboring a Rare HER2 Alteration May Benefit from anti-HER2 Therapy

JCO Research Round Up
April 22, 2013

New findings from a retrospective study suggest that targeted anti-HER2 therapy may slow disease progression in patients with advanced lung cancer who carry a specific alteration in HER2—a protein that controls cancer growth and spread, found on some cancer cells, such as breast, ovarian, and lung cancer cells.

Cetuximab Added to Chemotherapy Helps Some Patients With Advanced Colorectal Cancer That Has Spread to the Liver Live Longer

JCO Research Round Up
April 8, 2013

New findings from a clinical trial in patients with colorectal cancer and inoperable metastases in the liver (cancer that has spread from the colon or rectum to the liver) suggest that combination treatment with standard therapy and targeted drug cetuximab (Erbitux) caused significant shrinkage of metastases, making successful surgery feasible. Patients who received cetuximab in addition to traditional chemotherapy lived markedly longer than those who received only chemotherapy. 

Pages

Subscribe to RSS - Research Summaries